UCB SA (UCB.BR) Stock Fundamental Analysis
EBR:UCB - Euronext Brussels - BE0003739530 - Common Stock - Currency: EUR
Overall UCB gets a fundamental rating of 5 out of 10. We evaluated UCB against 53 industry peers in the Pharmaceuticals industry. UCB has an average financial health and profitability rating. While showing a medium growth rate, UCB is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
UCB had positive earnings in the past year.
UCB had a positive operating cash flow in the past year.
In the past 5 years UCB has always been profitable.
Each year in the past 5 years UCB had a positive operating cash flow.
1.2 Ratios
UCB's Return On Assets of 6.14% is in line compared to the rest of the industry. UCB outperforms 58.49% of its industry peers.
UCB has a Return On Equity (10.62%) which is in line with its industry peers.
The Return On Invested Capital of UCB (8.79%) is comparable to the rest of the industry.
The Average Return On Invested Capital over the past 3 years for UCB is significantly below the industry average of 15.31%.
The 3 year average ROIC (4.35%) for UCB is below the current ROIC(8.79%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.14% | ||
| ROE | 10.62% | ||
| ROIC | 8.79% |
ROA(3y)3.66%
ROA(5y)4.78%
ROE(3y)6.35%
ROE(5y)8.35%
ROIC(3y)4.35%
ROIC(5y)6.33%
1.3 Margins
UCB has a Profit Margin of 17.31%. This is in the better half of the industry: UCB outperforms 71.70% of its industry peers.
UCB's Profit Margin has been stable in the last couple of years.
UCB has a Operating Margin of 23.31%. This is in the better half of the industry: UCB outperforms 60.38% of its industry peers.
In the last couple of years the Operating Margin of UCB has declined.
UCB has a Gross Margin (71.52%) which is in line with its industry peers.
In the last couple of years the Gross Margin of UCB has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 23.31% | ||
| PM (TTM) | 17.31% | ||
| GM | 71.52% |
OM growth 3Y-15.5%
OM growth 5Y-9.39%
PM growth 3Y-1.86%
PM growth 5Y1.44%
GM growth 3Y-1.62%
GM growth 5Y-0.73%
2. Health
2.1 Basic Checks
UCB has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
Compared to 1 year ago, UCB has about the same amount of shares outstanding.
UCB has more shares outstanding than it did 5 years ago.
UCB has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 3.92 indicates that UCB is not in any danger for bankruptcy at the moment.
The Altman-Z score of UCB (3.92) is better than 62.26% of its industry peers.
UCB has a debt to FCF ratio of 3.29. This is a good value and a sign of high solvency as UCB would need 3.29 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 3.29, UCB is in the better half of the industry, outperforming 62.26% of the companies in the same industry.
UCB has a Debt/Equity ratio of 0.30. This is a healthy value indicating a solid balance between debt and equity.
With a decent Debt to Equity ratio value of 0.30, UCB is doing good in the industry, outperforming 67.92% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.3 | ||
| Debt/FCF | 3.29 | ||
| Altman-Z | 3.92 |
ROIC/WACC1.17
WACC7.49%
2.3 Liquidity
A Current Ratio of 1.36 indicates that UCB should not have too much problems paying its short term obligations.
UCB has a Current ratio (1.36) which is comparable to the rest of the industry.
UCB has a Quick Ratio of 1.36. This is a bad value and indicates that UCB is not financially healthy enough and could expect problems in meeting its short term obligations.
UCB has a Quick ratio of 0.99. This is comparable to the rest of the industry: UCB outperforms 49.06% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.36 | ||
| Quick Ratio | 0.99 |
3. Growth
3.1 Past
UCB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 18.57%, which is quite good.
The Earnings Per Share has been decreasing by -0.86% on average over the past years.
Looking at the last year, UCB shows a quite strong growth in Revenue. The Revenue has grown by 17.14% in the last year.
The Revenue has been growing slightly by 4.60% on average over the past years.
EPS 1Y (TTM)18.57%
EPS 3Y-8.45%
EPS 5Y-0.86%
EPS Q2Q%84.08%
Revenue 1Y (TTM)17.14%
Revenue growth 3Y2.12%
Revenue growth 5Y4.6%
Sales Q2Q%26.21%
3.2 Future
Based on estimates for the next years, UCB will show a very strong growth in Earnings Per Share. The EPS will grow by 27.05% on average per year.
UCB is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.38% yearly.
EPS Next Y48.96%
EPS Next 2Y37.44%
EPS Next 3Y34.53%
EPS Next 5Y27.05%
Revenue Next Year16.66%
Revenue Next 2Y14.56%
Revenue Next 3Y13.56%
Revenue Next 5Y11.38%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 32.68, UCB can be considered very expensive at the moment.
Based on the Price/Earnings ratio, UCB is valued a bit more expensive than the industry average as 60.38% of the companies are valued more cheaply.
When comparing the Price/Earnings ratio of UCB to the average of the S&P500 Index (26.55), we can say UCB is valued slightly more expensively.
With a Price/Forward Earnings ratio of 21.94, UCB is valued on the expensive side.
UCB's Price/Forward Earnings is on the same level as the industry average.
The average S&P500 Price/Forward Earnings ratio is at 22.30. UCB is around the same levels.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 32.68 | ||
| Fwd PE | 21.94 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of UCB is on the same level as its industry peers.
UCB's Price/Free Cash Flow ratio is in line with the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 34.41 | ||
| EV/EBITDA | 15.67 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
UCB's earnings are expected to grow with 34.53% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.67
PEG (5Y)N/A
EPS Next 2Y37.44%
EPS Next 3Y34.53%
5. Dividend
5.1 Amount
UCB has a yearly dividend return of 0.60%, which is pretty low.
Compared to an average industry Dividend Yield of 3.06, UCB has a dividend in line with its industry peers.
With a Dividend Yield of 0.60, UCB pays less dividend than the S&P500 average, which is at 2.39.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.6% |
5.2 History
The dividend of UCB has a limited annual growth rate of 2.46%.
Dividend Growth(5Y)2.46%
Div Incr Years6
Div Non Decr Years6
5.3 Sustainability
UCB pays out 24.32% of its income as dividend. This is a sustainable payout ratio.
UCB's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP24.32%
EPS Next 2Y37.44%
EPS Next 3Y34.53%
EBR:UCB (6/6/2025, 7:00:00 PM)
162.75
+0.05 (+0.03%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners40.15%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap31.66B
Analysts75
Price Target211.8 (30.14%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.6% |
Yearly Dividend1.36
Dividend Growth(5Y)2.46%
DP24.32%
Div Incr Years6
Div Non Decr Years6
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.12%
PT rev (3m)0.39%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)1.11%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.06%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 32.68 | ||
| Fwd PE | 21.94 | ||
| P/S | 5.15 | ||
| P/FCF | 34.41 | ||
| P/OCF | 25.49 | ||
| P/B | 3.16 | ||
| P/tB | 65.27 | ||
| EV/EBITDA | 15.67 |
EPS(TTM)4.98
EY3.06%
EPS(NY)7.42
Fwd EY4.56%
FCF(TTM)4.73
FCFY2.91%
OCF(TTM)6.39
OCFY3.92%
SpS31.63
BVpS51.56
TBVpS2.49
PEG (NY)0.67
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.14% | ||
| ROE | 10.62% | ||
| ROCE | 10.38% | ||
| ROIC | 8.79% | ||
| ROICexc | 10.16% | ||
| ROICexgc | 50.51% | ||
| OM | 23.31% | ||
| PM (TTM) | 17.31% | ||
| GM | 71.52% | ||
| FCFM | 14.95% |
ROA(3y)3.66%
ROA(5y)4.78%
ROE(3y)6.35%
ROE(5y)8.35%
ROIC(3y)4.35%
ROIC(5y)6.33%
ROICexc(3y)4.85%
ROICexc(5y)7.22%
ROICexgc(3y)28.31%
ROICexgc(5y)48.18%
ROCE(3y)5.15%
ROCE(5y)7.49%
ROICexcg growth 3Y-25.87%
ROICexcg growth 5Y-16.2%
ROICexc growth 3Y-19.14%
ROICexc growth 5Y-14.38%
OM growth 3Y-15.5%
OM growth 5Y-9.39%
PM growth 3Y-1.86%
PM growth 5Y1.44%
GM growth 3Y-1.62%
GM growth 5Y-0.73%
F-Score9
Asset Turnover0.35
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.3 | ||
| Debt/FCF | 3.29 | ||
| Debt/EBITDA | 1.43 | ||
| Cap/Depr | 50.23% | ||
| Cap/Sales | 5.23% | ||
| Interest Coverage | 8.96 | ||
| Cash Conversion | 59.86% | ||
| Profit Quality | 86.39% | ||
| Current Ratio | 1.36 | ||
| Quick Ratio | 0.99 | ||
| Altman-Z | 3.92 |
F-Score9
WACC7.49%
ROIC/WACC1.17
Cap/Depr(3y)52.98%
Cap/Depr(5y)82.03%
Cap/Sales(3y)5.99%
Cap/Sales(5y)6.61%
Profit Quality(3y)131.69%
Profit Quality(5y)119.05%
High Growth Momentum
Growth
EPS 1Y (TTM)18.57%
EPS 3Y-8.45%
EPS 5Y-0.86%
EPS Q2Q%84.08%
EPS Next Y48.96%
EPS Next 2Y37.44%
EPS Next 3Y34.53%
EPS Next 5Y27.05%
Revenue 1Y (TTM)17.14%
Revenue growth 3Y2.12%
Revenue growth 5Y4.6%
Sales Q2Q%26.21%
Revenue Next Year16.66%
Revenue Next 2Y14.56%
Revenue Next 3Y13.56%
Revenue Next 5Y11.38%
EBIT growth 1Y178.99%
EBIT growth 3Y-13.71%
EBIT growth 5Y-5.23%
EBIT Next Year142.1%
EBIT Next 3Y54.39%
EBIT Next 5Y34.91%
FCF growth 1Y106.74%
FCF growth 3Y-4.61%
FCF growth 5Y9.37%
OCF growth 1Y63.21%
OCF growth 3Y-7.18%
OCF growth 5Y7.09%